Cargando…
Epidrug Modulated Expression of MiR-152 and MiR-148a Reverse Cisplatin Resistance in Ovarian Cancer Cells: An Experimental In-vitro Study
Cisplatin is a common agent which is used to treat Epithelial Ovarian Cancer (EOC), but cisplatin resistance is a major obstacle in successful treatment of ovarian cancer. Aberration in epigenetic changes play an important role in disregulation of gene expression. MiR-152 and miR-148a are frequently...
Autores principales: | Khajehnoori, Sahel, Zarei, Fatemeh, Mazaheri, Mahta, Dehghani-Firoozabadi, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757992/ https://www.ncbi.nlm.nih.gov/pubmed/33680048 http://dx.doi.org/10.22037/ijpr.2020.15450.13217 |
Ejemplares similares
-
Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation
por: Zhou, Xin, et al.
Publicado: (2022) -
Prognostic value of expression levels of miR-148a, miR-152 and HLA-G in colon cancer
por: Emirzeoglu, Levent, et al.
Publicado: (2022) -
From animal models to patients: the role of placental microRNAs, miR-210, miR-126, and miR-148a/152 in preeclampsia
por: Frazier, Sonya, et al.
Publicado: (2020) -
miR-148a, miR-152 and miR-200b promote prostate cancer metastasis by targeting DNMT1 and PTEN expression
por: Gurbuz, Venhar, et al.
Publicado: (2021) -
Expression of the miR-148/152 Family in Acute Myeloid Leukemia and its Clinical Significance
por: Wang, Xiao-Xue, et al.
Publicado: (2017)